Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5285890, 11 pages
https://doi.org/10.1155/2017/5285890
Research Article

Gene Electrotransfer of Plasmid-Encoding IL-12 Recruits the M1 Macrophages and Antigen-Presenting Cells Inducing the Eradication of Aggressive B16F10 Murine Melanoma

1Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, Ljubljana, Slovenia
2Laboratory of Genetic and Clinical Pathology, University Campus Bio-Medico of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy
3Laboratory of Oncology, IRCCS “Casa Sollievo della Sofferenza”, Viale dei Cappuccini, 71013 San Giovanni Rotondo, Italy
4Faculty of Health Sciences, University of Primorska, Polje 42, Izola, Slovenia
5National Research Council-Institute of Translational Pharmacology (CNR-IFT), Via Fosso del Cavaliere 100, Rome, Italy

Correspondence should be addressed to Maja Cemazar; is.i-okno@razamecm and Emanuela Signori; ti.rnc.tfi@irongis.aleuname

Received 9 January 2017; Revised 3 March 2017; Accepted 12 March 2017; Published 17 May 2017

Academic Editor: Rafael E. Marques

Copyright © 2017 Ursa Lampreht Tratar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Vinay, E. P. Ryan, G. Pawelec et al., “Immune evasion in cancer: mechanistic basis and therapeutic strategies,” Seminars in Cancer Biology, vol. 35, pp. S185–S198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Gonzales-Gugel, M. Saxena, and N. Bhardwaj, “Modulation of innate immunity in the tumor microenvironment,” Cancer Immunology and Immunotherapy, vol. 65, no. 10, pp. 1261–1268, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. O. J. Finn, “Immuno-oncology: understanding the function and dysfunction of the immune system in cancer,” Annals of Oncology, vol. 23, no. 8, pp. viii6–viii9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kim and J. S. Bae, “Tumor-associated macrophages and neutrophils in tumor microenvironment,” Mediators of Inflammation, vol. 2016, Article ID 6058147, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. B. R. Achyut and A. S. Arbab, “Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer,” Journal of OncoTargets and Therapy, vol. 9, pp. 1047–1055, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. D. F. Soave, M. P. Miguel, F. Dias Tome, L. B. de Menezes, P. R. Nagib, and M. R. Celes, “The fate of the tumor in the hands of microenvironment: role of TAMs and mTOR pathway,” Mediators of Inflammation, vol. 2016, Article ID 8910520, 7 pages, 2016. View at Publisher · View at Google Scholar
  7. C. Devaud, L. B. John, J. A. Westwood, P. K. Darcy, and M. H. Kershaw, “Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy,” Oncoimmunology, vol. 2, no. 8, Article ID e25961, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. P. F. Forde, L. J. Hall, M. de Kruijf et al., “Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models,” Gene Therapy, vol. 22, no. 1, pp. 29–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Sersa, J. Teissie, M. Cemazar et al., “Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer,” Cancer Immunology and Immunotherapy, vol. 64, no. 10, pp. 1315–1327, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Chiarella, V. M. Fazio, and E. Signori, “Electroporation in DNA vaccination protocols against cancer,” Current Drug Metabolism, vol. 14, no. 3, pp. 291–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cemazar, T. Jarm, and G. Sersa, “Cancer electrogene therapy with interleukin-12,” Current Gene Therapy, vol. 10, no. 4, pp. 300–311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Cemazar, J. Ambrozic Avgustin, D. Pavlin et al., “Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours,” Veterinary and Comparative Oncology, 2016, Epub ahead of print. View at Publisher · View at Google Scholar · View at Scopus
  13. A. I. Daud, R. C. DeConti, S. Andrews et al., “Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5896–5903, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Trinchieri, S. Pflanz, and R. A. Kastelein, “The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses,” Immunity, vol. 19, no. 5, pp. 641–644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Pavlin, M. Cemazar, U. Kamensek, N. Tozon, A. Pogacnik, and G. Sersa, “Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma,” Cancer Biology & Therapy, vol. 8, no. 22, pp. 2114–2122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Tevz, S. Kranjc, M. Cemazar et al., “Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas,” The Journal of Gene Medicine, vol. 11, no. 12, pp. 1125–1137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Sedlar, T. Dolinsek, B. Markelc et al., “Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity,” Radiology and Oncology, vol. 46, no. 4, pp. 302–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. L. Lucas and R. Heller, “IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma,” DNA and Cell Biology, vol. 22, no. 12, pp. 755–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. A. Shirley, C. G. Lundberg, F. Li, N. Burcus, and R. Heller, “Controlled gene delivery can enhance therapeutic outcome for cancer immune therapy for melanoma,” Current Gene Therapy, vol. 15, no. 1, pp. 32–43, 2015. View at Google Scholar
  20. Y. I. Yamashita, M. Shimada, H. Hasegawa et al., “Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model,” Cancer Research, vol. 61, no. 3, pp. 1005–1012, 2001. View at Google Scholar
  21. S. Li, X. Zhang, and X. Xia, “Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy,” Journal of the National Cancer Institute, vol. 94, no. 10, pp. 762–768, 2002. View at Google Scholar
  22. W. K. Hubbard, Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications (Docket No 96-N-0400), Food and Drug Administration (FDA), Federal Register, Washington, MD, USA, 1996.
  23. European Medicines Agency (EMA), “Reflection paper on design modifications of gene therapy medicinal products during development,” 2011, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500122743.pdf. View at Google Scholar
  24. M. Bosnjak, L. Prosen, T. Dolinsek et al., “Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells,” Journal of Membrane Biology, vol. 246, no. 11, pp. 803–819, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. G. Williams, R. M. Cranenburgh, A. M. Weiss, C. J. Wrighton, D. J. Sherratt, and J. A. Hanak, “Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids,” Nucleic Acids Research, vol. 26, no. 9, pp. 2120–2124, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. U. Kamensek, N. Tesic, G. Sersa, S. Kos, and M. Cemazar, “Tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfer-mediated cancer immunotherapy,” Plasmid, vol. 89, pp. 9–15, 2017. View at Publisher · View at Google Scholar
  27. M. Cemazar, V. Todorovic, J. Scancar et al., “Adjuvant TNF-alpha therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness,” Radiology and Oncology, vol. 49, no. 1, pp. 32–40, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. M. De Robertis, M. Arigoni, L. Loiacono et al., “Novel insights into Notum and glypicans regulation in colorectal cancer,” Oncotarget, vol. 6, no. 38, pp. 41237–41257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Wang, N. Ma, W. Zhao et al., “Inflammation-related DNA damage and cancer stem cell markers in nasopharyngeal carcinoma,” Mediators of Inflammation, vol. 2016, Article ID 9343460, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Chiarella, E. Massi, M. De Robertis et al., “Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration,” Expert Opinion on Biological Therapy, vol. 8, no. 11, pp. 1645–1657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Chávez-Galán, M. L. Olleros, D. Vesin, and I. Garcia, “Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages,” Frontiers in Immunology, vol. 6, p. 263, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Sedlar, S. Kranjc, T. Dolinsek, M. Cemazar, A. Coer, and G. Sersa, “Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma,” BMC Cancer, vol. 13, no. 1, p. 38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Lucas, L. C. Heller, D. Coppola, and R. Heller, “IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma,” Molecular Therapy, vol. 5, no. 6, pp. 668–675, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. W. A. Selleck, S. E. Canfield, W. A. Hassen et al., “IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach,” Molecular Therapy, vol. 7, no. 2, pp. 185–192, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Wang, S. Saffold, X. Cao, J. Krauss, and W. Chen, “Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines,” The Journal of Immunology, vol. 161, no. 10, pp. 5516–5524, 1998. View at Google Scholar
  36. G. D. Scarpati, C. Fusciello, F. Sabbatino et al., “Multidisciplinary approach to patient with malignant melanoma,” Anticancer Agents in Medicinal Chemistry, vol. 13, no. 6, pp. 887–900, 2013. View at Publisher · View at Google Scholar · View at Scopus